Lilly/Sepracor Prozac Agreement Suggests Limits Of FTC Patent Inquiries

The Federal Trade Commission's approval of Lilly and Sepracor's (R)-fluoxetine agreement suggests that the agency's recent concern with patent defense strategies will not extend to evergreen deals.